Atosiban competitively binds to oxytocin receptors on uterine smooth muscle, effectively blocking oxytocin-induced uterine contractions, thus giving the fetus more time to develop and reducing the risk of premature birth. Compared to traditional tocolytic drugs, its advantages lie in its milder side effects and lower risk of causing heart rate increases or electrolyte imbalances, making it safer. However, atosiban is expensive, with a single course of treatment costing tens of thousands of yuan, and must be used strictly according to the doctor's instructions. It is usually administered intravenously, with a treatment duration not exceeding 48 hours and a total dose not exceeding 330 mg. During medication, close monitoring of uterine contraction frequency, fetal heart rate, and maternal vital signs is necessary. If persistent contractions or adverse reactions occur, the treatment plan must be adjusted promptly.
If a pregnant woman experiences regular contractions, cervical changes, or other signs of premature labor between 24 and 33 weeks of gestation, she should seek medical evaluation immediately. The doctor will consider gestational age, cervical condition, and fetal status to comprehensively determine whether atosiban is suitable and develop an individualized tocolytic plan.
